Akero Therapeutics (AKRO) reported a Q1 net loss Monday of $0.90 per diluted share, unchanged from a year earlier.
Analysts polled by FactSet expected $1.02 loss.
The company did not report any revenue for the quarter ended March 31.
As of March 31, the company said it had $1.13 billion in cash, cash equivalents, and short- and long-term marketable securities, expected to fund operations into 2028.
The company's shares were up 4.1% in recent premarket activity Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。